Portfolio News
Sofinnova Crossover & Sofinnova Industrial Biotech
Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs
Synthace raises £7.3m to accelerate biotechnology to enable faster breakthroughs
Related Company
SynthaceRelated Strategy
CrossoverRelated Strategy
Industrial BiotechRelated Deal lead
Joško BobanovićRelated News
Bionyra Pharma announces first healthy volunteers dosed in Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis
NodThera changes name to Rezera Inc. and announces Ruvonoflast Phase 3 development program
ProQR announces first participant dosed in Phase 1 study of AX-0811
Rezera announces Ruvonoflast met primary inflammation endpoint and demonstrated favorable safety profile in trial
Neurent Medical secures €25 million growth debt facility from Claret Capital Partners to accelerate commercial expansion